Medro vs Pallas Health
Two GLP-1 desks, one scoreboard. We put Medro and Pallas Health head-to-head on the published Brief Score — the same six factors, scored the same way.
Medro
The verdict
Medro takes this head-to-head.
Medro scores 68 to 63 on our six-factor Brief Score — Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…
That doesn't make Pallas Health a bad call — it's best for readers who can absorb $597 in a single charge every 12 weeks and want a desk that will tell them who compounds and who prescribes — not readers budgeting a predictable monthly bill. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Medro | Pallas Health | |
|---|---|---|
| Brief Score | 68/100 (C) | 63/100 (C) |
| Semaglutide | From $199/mo (compounded) | $199/mo average, compounded — but it bills $597 every 12 weeks, not monthly ($139 first 4 weeks) |
| Tirzepatide | From $299/mo (compounded) | $299/mo average, compounded — but it bills $897 every 12 weeks, not monthly ($179 first 4 weeks) |
| Coverage | All 50 states | Nationwide — all 50 states + DC |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Newnew to the tracker, no prior reading | Newnew to the tracker, no prior reading |
Medro: New to the tracker on 1 August 2026. The published line reads From $199/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
Pallas Health: First reading, 7 August 2026. The advertised averages are $199/mo semaglutide and $299/mo tirzepatide, but no month-to-month plan exists to buy: the charge is $139 up front, then $597 every 12 weeks from four weeks after approval ($179, then $897, on tirzepatide). Because an 84-day cycle recurs 4.35 times a year rather than four, those renewal terms work out at roughly $216 and $325 a month once the intro period is behind you.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.